[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR900015724A - 메베버린 용량 형태 - Google Patents

메베버린 용량 형태 Download PDF

Info

Publication number
KR900015724A
KR900015724A KR1019900005458A KR900005458A KR900015724A KR 900015724 A KR900015724 A KR 900015724A KR 1019900005458 A KR1019900005458 A KR 1019900005458A KR 900005458 A KR900005458 A KR 900005458A KR 900015724 A KR900015724 A KR 900015724A
Authority
KR
South Korea
Prior art keywords
composition
meveyverine
lumen
human
administered
Prior art date
Application number
KR1019900005458A
Other languages
English (en)
Inventor
게리 멘델 케네트
제임스 쉘던 러셀
Original Assignee
리챠드 챨스 위트
더 프록터 앤드 갬블 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리챠드 챨스 위트, 더 프록터 앤드 갬블 캄파니 filed Critical 리챠드 챨스 위트
Publication of KR900015724A publication Critical patent/KR900015724A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

내용 없음.

Description

메베버린 용량 형태
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. (a) 안전하고 유효한 양의 메베버린(Mebeverine)과 (b) 당해 조성물이 투여된 후 메베버린을 위장관을 통해 이의 하향 부위로 운반하고 위장관의 하향 부위의 내강에서 메버버린 유효량을 방출시키는 약제학적으로 허용되는 담체를 포함하는, 하향 부위와 이를 통과하는 내강이 있는 위장관을 갖는 사람 또는 하등동물에게 메베버린을 경구 투여하기 위한 용량 단위 형태의 약제학적 조성물.
  2. 제1항에 있어서, (a) 메베버린을 함유하고 메베버린의 방출속도를 조절하는 코어(Core) 조성물과 (b) 용량 단위 형태가 위에 존재하지 않는 이후까지 코어 조성물로부터 전체 메베버린의 방추를 실질적으로 지연시키는 타켓팅(Targetting) 조성물을 포함하는 조성물.
  3. 제2항에 있어서, 코어 조성물이 타켓팅 조성물안에 감싸인 조성물.
  4. 제3항에 있어서, 코어 조성물이 분산된 분말을 포함하는 조성물.
  5. 제3항에 있어서, 코어 조성물이 펠릿을 포함하는 조성물.
  6. 제3항에 있어서, 코어 조성물이 압착 정제를 포함하는 조성물.
  7. 제3항에 있어서, 타겟팅 조성물이 용량 단위 형태가 공장을 통과한 이후까지 코어 조성물로부터 메베버린의 방출을 지연시키는 조성물.
  8. 제1항에 내지 제7항중의 어느 한 항에 있어서, 메베버린이 메베버린 염산염인 조성물.
  9. 제2항에 내지 제7항중의 어느 한 항에 있어서, 코어 조성물이 메베버린의 지속적인 방출을 제공하는 조성물.
  10. 제2항에 내지 제7항중의 어느 한 항에 있어서, 타겟팅 조성물이 pH-민감성 장 물질을 포함하는 조성물.
  11. 하향 위정관과 이를 통과하는 내강을 갖는 사람 또는 하등동물의 하향 위장관의 내강에 안전하고 유효한 양의 메베버린을 국소운반하여 사람 또는 하등동물의 기능성장/결장질환을 치료하는 방법.
  12. 제11항에 있어서, 기능성 장/결장질환이 흥분성 장 증후군인 방법.
  13. 제12항에 있어서, 메베버린이 경구 투여하는 방법.
  14. 제13항에 있어서, 약 20 내지 약 200mg/1일의 메베버린이 사람에게 투여되는 방법.
  15. 제13항에 있어서, 약 200 내지 약 600mg/1일의 메베버린이 사람에게 투여되는 방법.
  16. 제13항에 있어서, 약 200 내지 약 400mg/1일의 메베버린이 사람에게 투여되는 방법.
  17. 결장과 이를 통과하는 내장을 갖는 사람 또는 하등동물에게 실질적인 운동장애활성을 일으키지 않으면서 실질적인 진경 활성이 획득되는 양의 메베버린을 국소 운반하여 사람 또는 하등동물의 기능성 장/결장질환을 치료하는 방법.
  18. 제17항에 있어서, 약 0.01 내지 약 30mg/kg의 메베버린이 약 0 내지 약 12시간에 걸쳐 결장의 내강에 국소투여되는 방법.
  19. 제17항에 있어서, 약 0.01 내지 약 1mg/kg의 메베버린이 약 0 내지 약 4시간에 걸쳐 결장의 내강에 국소투여되는 방법.
  20. 제19항에 있어서, 약 1 내지 약 10mg/kg의 메베버린이 약 2 내지 약 8시간에 걸쳐 결장의 내강에 국소투여되는 방법.
  21. 제19항에 있어서, 약 0.3 내지 약 3mg/kg의 메베버린이 약 1 내지 약 6시간에 걸쳐 결장의 내강에 국소투여되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900005458A 1989-04-20 1990-04-19 메베버린 용량 형태 KR900015724A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34133889A 1989-04-20 1989-04-20
US341338 1989-04-20
US48347290A 1990-02-27 1990-02-27
US483472 1990-02-27

Publications (1)

Publication Number Publication Date
KR900015724A true KR900015724A (ko) 1990-11-10

Family

ID=26992461

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900005458A KR900015724A (ko) 1989-04-20 1990-04-19 메베버린 용량 형태

Country Status (7)

Country Link
EP (1) EP0393747A3 (ko)
JP (1) JPH032119A (ko)
KR (1) KR900015724A (ko)
CN (1) CN1046459A (ko)
AU (1) AU5369790A (ko)
PE (1) PE33190A1 (ko)
PT (1) PT93637A (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623780B2 (ja) * 1989-09-21 1994-03-30 日本電装株式会社 半導体加速度センサの製造方法
ZA919510B (en) * 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
EP0528076A1 (en) * 1991-08-20 1993-02-24 Duphar International Research B.V Use of Mebeverine against non-specific inflammatory bowel disease
NZ255579A (en) * 1992-09-18 1996-03-26 Yamanouchi Pharma Co Ltd Sustained release hydrogel pharmaceutical formulation
FI98343C (fi) * 1995-03-21 1997-06-10 Orion Yhtymae Oy Peroraalinen formulaatio
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
DE102005032806A1 (de) * 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
JP4918651B2 (ja) * 2008-01-07 2012-04-18 株式会社サカエ 組立台車
DE102009028076A1 (de) * 2009-07-29 2011-02-03 Evonik Röhm Gmbh Beschichtungsmittel zum Tauchbeschichten von Kapselhälften
US9107451B2 (en) 2009-07-29 2015-08-18 Evonik Röhm Gmbh Coating composition for the dip coating of capsule halves
WO2014007776A1 (en) * 2012-07-02 2014-01-09 Mahmut Bilgic Antispasmodic modified release formulations
US20150037385A1 (en) * 2013-08-02 2015-02-05 Northwestern University Ceramic-containing bioactive inks and printing methods for tissue engineering applications
JP6542807B2 (ja) 2014-05-15 2019-07-10 ノースウェスタン ユニバーシティ ３次元印刷のためのインク組成物及び前記インク組成物を使用してオブジェクトを形成する方法
WO2016085584A2 (en) 2014-10-15 2016-06-02 Northwestern University Graphene-based ink compositions for three-dimensional printing applications
WO2016164523A1 (en) 2015-04-07 2016-10-13 Northwestern University Ink compositions for fabricating objects from regoliths and methods of forming the objects

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1218102A (en) * 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS6261916A (ja) * 1985-09-12 1987-03-18 Fujisawa Pharmaceut Co Ltd 持続性製剤

Also Published As

Publication number Publication date
EP0393747A3 (en) 1991-07-31
PE33190A1 (es) 1991-01-10
PT93637A (pt) 1990-11-20
JPH032119A (ja) 1991-01-08
AU5369790A (en) 1990-10-25
CN1046459A (zh) 1990-10-31
EP0393747A2 (en) 1990-10-24

Similar Documents

Publication Publication Date Title
KR900015724A (ko) 메베버린 용량 형태
US4289751A (en) Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
US4757060A (en) Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
US4066756A (en) Therapeutic compositions of 1,3-bis(2-carboxychromon-5-yloxyl)propan-2-ol and aspirin or indomethacin
ES2401366T3 (es) Método para tratamiento de síndrome del intestino irritable con estreñimiento predominante
EP0980246B1 (en) Therapy for constipation
Turck et al. Comparison of racecadotril and loperamide in children with acute diarrhoea
PL173485B1 (pl) Środek farmaceutyczny do leczenia nieżytu żołądka i wrzodu trawiennego
Van de Mierop et al. Oral domperidone in chronic postprandial dyspepsia: A double-blind placebo-controlled evaluation
ATE201991T1 (de) Bisacodyl dosierungsform
KR850700212A (ko) 서방성 약제학적 캼셀제
IE48945B1 (en) Pharmaceutical preparations containing a mollusc extract
Pellissier et al. Oxyntomodulin and glicentin are potent inhibitors of the fed motility pattern in small intestine
US672672A (en) Medicated salt rock.
JP2007112795A (ja) アントラキノン系薬剤含有下剤医薬組成物
ES2356371T3 (es) Medicamentos terapéuticos para inducir tolerancia.
WO2001049269A1 (en) Sustained-releasing anthelmintic compositions comprising praziquantel
KR101254511B1 (ko) 위장약 조성물
JP2586542B2 (ja) 牛の第四胃変位の治療剤
Oberst et al. Evaluation of botulinum antitoxin, supportive therapy, and artificial respiration in monkeys with experimental botulism
Cohen Marijuana: does it have a possible therapeutic use?
EP0321613A1 (en) The effect of a combination of a beta-adrenergic agonist and certain histamine H1- and/or H2-receptor blockers on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
CN104873485B (zh) 槲皮素治疗与胃肠道应激失调相关疾病的用途
JP2004059579A (ja) 鎮痛剤組成物
JP2586922B2 (ja) ある種のｈ▲下１▼およびｈ▲下２▼受容体遮断剤の組合せにより消化管損傷に対して保護された非ステロイド系抗炎症組成物

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid